Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded higher in the premarket on Friday after Scotiabank upgraded the biotech to Sector Outperform from Sector Perform, citing a compelling risk-reward ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Developed by Sarepta Therapeutics, Elevidys is a one-time, intravenous treatment that uses adeno-associated virus (AAV) technology to deliver a gene designed to produce a shortened form of the ...

Sarepta Therapeutics (NASDAQ:SRPT) and its partner Roche (OTCQX:RHHBY) received a 'go ahead' from the regulatory body in U.K.

Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking ...

In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in ...

The approval is based on Phase 3 EPIDYS trial data that demonstrated meaningful treatment benefits in ambulant patients ...

For nearly a decade, Sarepta has been a leader in advancing the treatment of Duchenne muscular dystrophy through innovative treatment options. With the approval of ELEVIDYS in Japan, children who ...

“For nearly a decade, Sarepta has been a leader in advancing the treatment of Duchenne muscular dystrophy through innovative treatment options. With the approval of ELEVIDYS in Japan, children ...